Janus kinase (JAK) inhibitors are a new addition in the armamentarium of drugs in the treatment of autoimmune dermatoses. They have proven to be valuable in treating a variety of inflammatory dermatoses with lesser side effects compared to their biological counterparts. This review throws light on JAK inhibitors and their role in dermatologic diseases. 
With the emergence of new molecular targeted therapies, the picture of therapeutic dermatology is gradually evolving. One such molecular target is the Janus kinase-signal transducer and activation of transcription (JAK-STAT) pathway.
A number of inflammatory dermatoses rely on the JAK-STAT pathway for their pathogenesis. Therefore, utilizing JAK inhibitors may prove to be valuable in targeting the pathogenesis of these disorders. A number of JAK inhibitors have been utilized. Broadly, they have been classified into first-generation JAK inhibitors that include tofacitinib, ruxolitinib, baricitinib, and oclacitinib and second-generation JAK inhibitors that comprise decernotinib, peficitinib, filgotinib, fedratinib, momelotinib, and lestaurtinib. Currently, only the first-generation JAK inhibitors are being utilized in the management of dermatological disorders and are lucidly outlined in Table 1 . The second-generation JAK inhibitors at present are in their developmental stage.
MechAnisM of Action

In atopic dermatitis
It has been proved that JAK-STAT signaling pathway enhances release of interleukin (IL)-4, IL-5 and IL-13, which play an important role in stimulating T H 2 differentiation. In experimental models, tofacitinib and oclacitinib have demonstrated an antagonizing effect on the release of the above cytokines, thereby blocking their inflammatory activity. [6] [7] [8] 
In alopecia areata
In alopecia areata (AA), JAK-STAT-dependent cytokines along with interferon (IFN) γ and IL-15 activate autoreactive T-cells. [9] JAK inhibition can prevent the release of these inflammatory cytokines, thereby bringing a halt to the pathogenetic process.
In psoriasis
IL-12 and IL-23 are JAK-STAT-dependent cytokines which majorly serve as inflammatory mediators in psoriasis. Further, IL-23 stimulates T H 17 cells to produce IL-17, another important pathogenic molecule in psoriasis. Although IL-17 does not directly rely on JAK-STAT signaling pathway, blockade of IL-23 by JAK inhibitors reduces IL-17, and therefore, these drugs have value in psoriasis. [6, 10, 11] 
In vitiligo
It has been demonstrated that depigmentation in vitiligo is mediated by IFN γ-induced expression of C-X-C motif chemokine 10 (CXCL 10) in keratinocytes. [12] As IFN γ signal transduction occurs through JAK 1 and 2, blockade of JAK with tofacitinib inhibits IFN γ signaling, thereby downregulating CXCL 10 expression, leading to return in pigmentation.
phArMAcokinetics
As tofacitinib is the prototype drug for JAK inhibitors, its pharmacokinetics are discussed in this section. Tofacitinib is rapidly absorbed after oral administration with plasma levels peaking after 1 h of oral intake. Tofacitinib has been demonstrated to have a mean terminal plasma half-life of 3.2 h. Metabolism of tofacitinib occurs in the liver by oxidation, N-demethylation, and glucuronidation. Elimination of tofacitinib occurs via both the hepatic (70%) and renal (30%) routes. [14] indicAtions
Food and Drug Administration approved
• Rheumatoid arthritis (tofacitinib, baricitinib) • Myelofibrosis and polycythemia rubra vera (ruxolitinib).
Off label
• All cutaneous indications as mentioned below.
contrAindicAtions
Absolute
• Hypersensitivity to the drug.
Relative
• Liver impairment • Stage IV kidney disease • Active infections.
Pregnancy prescribing status
• Category "C."
clinicAl uses
Atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory condition of the skin associated with significant pruritus. [15] It affects around 10%-30% patients in the pediatric age group and around 1%-3% of the adult population. [16] Currently, the mainstay of pharmacologic therapy in AD comprises topical corticosteroids, topical calcineurin inhibitors, and phototherapy, with systemic immunosuppressive drugs such as cyclosporine, methotrexate, mycophenolate mofetil, and azathioprine being added to the therapeutic armamentarium in recalcitrant cases. [17, 18] These therapies, however, are often insufficient for moderate-to-severe disease. [19, 20] Recent advances in the pathogenesis of AD have demonstrated the utility of tofacitinib, both topically and systemically as a new targeted therapeutic modality for AD.
Levy et al. [21] have reported the clinical efficacy of systemic tofacitinib in six patients aged between 18 and 55 years, with moderate-to-severe AD who were resistant to previous therapies with other immunosuppressive drugs as mentioned above. In these patients, tofacitinib was administered at a dose of 5 mg PO twice daily or once daily, along with concomitant use of topical corticosteroids which resulted in 66.6% reduction in the severity scoring of AD index and 69.9% reduction in pruritus and sleep loss. This was observed after 8-29 weeks of treatment. During this limited series, no adverse events were observed.
A recently published study utilizing 2% tofacitinib ointment in 69 adult patients with mild-to-moderate AD resulted in 81.7% diminution of the eczema area and severity index score at 4 weeks relative to a decrease of 29.9% in the placebo group. [22] In both the above observations, a stable and significant improvement of the disease was witnessed. Further, a favorable adverse effect profile was also documented in both reports. However, larger randomized controlled trials would be required to further establish the safety profile and efficacy of systemic tofacitinib for moderate-to-severe AD.
Alopecia areata
AA is an autoimmune disorder demonstrating patches of nonscarring alopecia that can involve any area of the body. [23] Currently, no particular treatment has been approved by the US Food and Drug Administration (FDA) for the management of AA. Many off-label treatments are available, but the efficacy of most of them is limited, thereby making room for newer alternatives in treating AA. Increasing evidence elucidates avaluable and effective contribution by JAK inhibitors in the treatment of AA and is summarized in Table 2 .
Psoriasis
Psoriasis is a common, chronic, inflammatory disease of multifactorial origin affecting 1%-3% of the world's population. Chronic plaque psoriasis is the most common manifestation of the disease that is clinically characterized by well-defined erythematous and scaly plaques.
Despite there being a number of treatments available for psoriasis, additional therapeutic options with a distinctive targeted effect would certainly be of value in managing the disease. [35] It has also been observed that the overall efficacy of tumor necrosis factor (TNF)-α blockers diminishes over time owing to their potential immunogenicity. [36] Further, the body mass index also affects the long-term survival rate of TNFα antagonists in patients with psoriasis. [37] Recently, attention has shifted to newer compounds targeting signaling pathways such as JAK inhibitors. These small Tofacitinib First studied as an antirejection agent in organ transplant [1] First FDA-approved JAK inhibitor for the treatment of RA Ruxolitinib FDA approved for the treatment of myelodysplastic disorders Baricitinib Approved by the FDA for RA in June 2018 However, currently in phase 2 trials for psoriasis and AD [2, 3] Oclacitinib No approved indications in humans Has been used to treat AD in dogs [4, 5] JAK: Janus kinase, RA: Rheumatoid arthritis, AD: Atopic dermatitis, FDA: Food and Drug Administration [25] Ruxolitinib 20 mg PO Q12H in 12 patients aged between 29 and 58 years, with moderate to severe AA
3-6 months
A remarkable response to treatment was observed in 9 patients with an average hair re-growth of 92% at the end of treatment In the remaining three patients, there was no response to ruxolitinib Safety parameters remained largely within normal limits with no serious adverse effects being reported Dhayalan and King [26] 3 patients aged between 20 and 40 years with alopecia universalis and nail dystrophy treated with tofacitinib 5 mg PO Q12H
5-6 months
Remission of nail dystrophy in all 3 patients treated Hair re-growth observed in only 2 patients Tofacitinib was well tolerated in all 3 cases with no serious adverse effects being reported Craiglow et al. [27] Topical ruxolitinib 0.6% cream applied twice daily on eyebrows and scalp in a patient in her late teens with alopecia universalis
weeks
Complete eyebrow regrowth Partial scalp hair regrowth (around 10%) Apart from a small stable reduction in the white blood cell count, no other adverse effects were reported Craiglow and King [28] A 25-year-old male patient with plaque-type psoriasis and alopecia universalis treated with oral tofacitinib 15 mg PO per day 8 months
Complete regrowth of scalp and body hair, eyebrow and eye lashes Tofacitinib was well tolerated with no serious adverse effects being reported Liu et al. [29] 90 patients aged between 18-70 years with AA and its variants treated with oral tofacitinib 5 mg twice daily for at least 3 months
4-18 months
Out of 90 patients, 65 were considered potential responders and 25 of them were unlikely to respond with tofacitinib If hair growth was observed after 3 months, then the same standard dosing was continued Out of these 65 patients; in 13 patients there was a >90% reduction in the SALT score, in 25 patients there was a 51%-90% reduction in the SALT score, in 12 patients there was a 6%-50% reduction in the SALT score and in the remaining 15 patients the SALT score reduction was <5%
If not, then the dose was escalated to a maximum of 20 mg of tofacitinib in 2 divided doses with or without prednisolone that was dosed as a single 300 mg monthly dose for 3 doses Anzengruber et al. [30] Tofacitinib 5 mg given PO Q12H in a 55-year-old male patient with alopecia universlis 6 months Patient had terminal hair growth after 3 months of initiation of therapy with tofacitinib, but returned to baseline after 4 months despite the drug being continued Jabbari et al. [31] Tofacitinib 5 mg PO Q12H administered to a 40-year-old female patient with persistent moderate to severe AA
months
By the end of 4 months, re-growth of scalp hair was nearly complete with significant regrowth of eyebrows and eyelashes However, after cessation of treatment hair loss returned to baseline Mrowietz et al. [32] A 20-year-old female patient with alopecia universalis, plaque-type psoriasis and psoriatic arthritis who was treated with oral tofacitinib 15 mg/day for 6 weeks followed by 10 mg/day 9 months
Complete resolution of alopecia universalis by 6 months of treatment Complete resolution of dactylitis and no symptoms of psoriatic arthritis remaining Psoriatic plaques however did not respond to tofacitinib, for which low-dose oral fumaric acid ester therapy was instituted that enabled those plaques to resolve Patient developed herpes zoster while on tofacitinib and was treated with brivudine; however, this episode did not warrant discontinuation of therapy with tofacitinib Craiglow et al. [33] Oral tofacitinib given at a dose of 5mg Q12H in 13 adolescent patients with AA and its variants
2-16 months
Out of the 13 patients, 9 patients achieved significant hair growth with 100% change in the SALT score
Contd... molecular weight inhibitors are synthetic compounds that are relatively inexpensive and can be administered both topically and systemically. [38] They have been utilized in psoriasis with promising results. The FDA has yet to approve tofacitinib for this indication. Various studies depicting the utility of JAK inhibitors for psoriasis are summarized in Table 3 .
Vitiligo
Vitiligo is an autoimmune disease associated with skin and mucosal depigmentation. Though not a life-threatening disease, vitiligo is associated with profound psychological implications on the patient's quality of life. Available treatment options for vitiligo are limited and often inadequate. Recent studies on the pathogenesis of vitiligo have suggested the possibility of JAK inhibitors as an effective therapy for the same. [12] Harris et al. [47] have reported significant repigmentation of vitiligo in a patient with both AA and vitiligo with administration of ruxolitinib 20 mg PO twice daily for 24 weeks. However, depigmentation recurred after discontinuation of the drug.
Another case report by Craiglow and King [48] demonstrated the promising effect of tofacitinib in vitiligo vulgaris in a middle-aged woman who had been unresponsive to topical triamcinolone (0.1%), topical tacrolimus (0.1%), and narrow-band ultraviolet B (UVB) phototherapy. Tofacitinib was first initiated at a dose of 5 mg PO on alternate days for 3 weeks, followed by 5 mg/day for 5 months. After the stated duration, patient experienced nearly complete repigmentation over the forehead and hands and only 5% of the total lesions overall remained depigmented. Further, the safety profile of the drug was also favorable.
Also, rapid repigmentation of vitiligo utilizing tofacitinib along with low-dose narrow band UVB has been documented by Kim et al., [49] thereby demonstrating synergism while combining these treatment modalities.
Dermatomyositis
Studies have suggested the role of tofacitinib in refractory cutaneous dermatomyositis (DM). Tofacitinib acts by suppressing the abnormally upregulated IFN signaling in DM. [50, 51] In one series, three patients with refractory DM observed clinical response after treatment with oral tofacitinib at a dose of 5-10 mg/day. The mean treatment period was 9.6 months. By the end of 4 weeks of treatment, clinical improvement was noticeable with respect to pruritus and muscle strength. [52] Improvement from moderate-to-severe to mild disease was observed in two patients. In both these patients, tofacitinib was employed as monotherapy after failure of previous conventional therapies. The third patient demonstrated a lesser response though the response was clinically significant.
In a case report by Hornung et al., [53] ruxolitinib was used to treat recalcitrant DM in a 72-year-old patient who also had polycythemia rubra vera and myelofibrosis. Here, ruxolitinib was administered at a dose of 5 mg PO Q12H for 2 months, which was then increased to 15 mg PO Q12H for 12 months, followed by 10 mg twice daily. Therapy with ruxolitinib was associated with improvement of both cutaneous and musculoskeletal symptoms of DM. Further, no adverse effects were reported in this patient.
Lichen planopilaris
Lichen planopilaris (LPP) is an inflammatory cicatricial alopecia of unclear etiology, whose treatment still remains a challenge. Many different treatment modalities have been advocated for LPP with varying success. A recent study has demonstrated upregulation of JAK1 and JAK3 in dermal inflammatory cells of LPP, thereby postulating a role of JAK inhibitors in reducing IFN-mediated inflammation associated with LPP and in this way preventing further destruction of hair follicles. [54] In a case series of 10 patients of LPP (aged between 33 and 68 years) treated with oral tofacitinib (10-15 mg/day) for 2-9 months, improvement in erythema, scaling, and hair density was witnessed in eight out of 10 patients. Further, symptoms such as pruritus, pain, and burning demonstrated significant reduction. Of these 10 patients, five received tofacitinib monotherapy with the remaining five also receiving intralesional triamcinolone (2 patients), hydroxychloroquine (1 patient), hydroxychloroquine and triamcinolone (1 patient), and intralesional triamcinolone with topical tacrolimus (1 patient). In all patients, treatment with tofacitinib was well tolerated with no adverse effects being reported. [55] 
Lupus erythematosus
In a case report by Wenzel et al., [56] ruxolitinib dosed at 20 mg PO Q12H for 4 months in a 69-year-old patient with chilblain lupus was associated with complete remission of the condition.
speciAl considerAtion
Use of Janus kinase inhibitors in the pediatric population
In most of the studies pertaining to JAK inhibitors, it has been seen that either adults or adolescents constituted the study population. However, there are a few reports depicting the 
Author (s) Study details Duration of treatment Remarks
Jabbari et al. [34] Oral baricitinib given at a dose of 7 mg/day for 6 months followed by 7 mg once in the morning and 4 mg at night for 12 months in a 17-year-old female patient with CANDLE syndrome with long-standing patchy AA 18 months Regrowth of hair was noticeable in all patches except for one occipital patch by 3 months In that occipital patch, gradual regrowth was seen in the next 9 months, with the response being maintained during the period of therapy SALT: Severity of alopecia tool, CANDLE: Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature, AA: Alopecia areata [39] Tofacitinib given as two PO dosing schedules in 1106 patients with moderate to severe plaque psoriasis Group A -5mg Q12H Group B -10mg Q12H 12 weeks PASI 75 response was 39.5% and 63.6% in group A and group B respectively Tofacitinib 10 mg Q12H was found to be equivalent to etanercept 50 mg (subcutaneous) twice weekly, in efficacy Papp et al. [3] Baricitinib given at 8 mg PO once daily (Group A), and 10 mg PO once daily (Group B) in 271 patients with moderate to severe plaque psoriasis 12 weeks PASI 75 responses of 43% and 54% in Group A and B respectively Punwani et al. [40] Topical ruxolitinib 1%-1.5% cream applied twice daily in 25 patients with chronic plaque psoriasis involving 2%-20% of the BSA 4 weeks Major reduction in size of psoriatic plaques was observed Ports et al. [41] Topical 2% tofacitinib ointment applied twice daily in 71 patients with mild to moderate chronic plaque psoriasis 4 weeks Improvement of psoriasis Menter et al. [42] Oral tofacitinib administered at various dosing schedules of 2 mg, 5 mg or 15 mg twice daily in 197 patients with moderate to severe plaque psoriasis 12 weeks Target plaque severity score improved in both responsive and unresponsive areas with all dosing schedules when compared with placebo Mamolo et al. [43] Oral [45] Oral tofacitinib administered in 2 dosing schedules in 1843 patients with moderate to severe plaque psoriasis
weeks
Efficacy of tofacitinib was observed in both groups Greater improvement was witnessed in the 10 mg Q12H dosing group increased weight and prior treatment with biologic agents were associated with lower response rates 5 mg PO Q12H 10 mg PO Q12H Valenzuela et al. [46] Comparative study between oral tofacitinib (5 mg and 10mg Q12H) and etanercept in 1101 patients with moderate to severe plaque psoriasis 12 weeks Improvement in DLQI was 47.3% with tofacitinib (10 mg dosing) and 43.6% with etanercept Pruritus was much less in the tofacitinib group when compared to etanercept PASI: Psoriasis area severity index, BSA: Body surface area, DLQI: Dermatology life quality index [57] Administration of ruxolitinib in 3 patients aged between 5-12 years diagnosed with stimulator of interferon genes associated vasculopathy with onset in infancy 6-18 months In all 3 patients, improvement was noticed in cutaneous, pulmonary, and inflammatory manifestations of the disease In one patient papillary edema secondary to intracranial hypertension was observed and it was not clear whether this effect was related to ruxolitinib or not Bayart et al. [58] In 6 patients with alopecia areata aged between 3 and 17 years either topical tofacitinib (1%-2%) or ruxolitinib (1%-2%) was applied twice daily over the bald patches [59] An 8-year-old boy with alopecia areata progressing to alopecia universalis after failed treatment with topical and intralesional steroids was started with oral tofacitinib 5 mg Q12H along with topical clobetasol 0.05% solution 6 months After 6 months of treatment, 100% regrowth of scalp and eyebrow hair was observed However, after 6 months, the patient did not continue the drug owing to a mild headache which the family attributed to the drug The patient was subsequently lost to follow-up utility of these drugs in children and have been elaborated in Table 4 . Though not associated with major adverse responses, the use of systemic JAK inhibitors should be exercised with caution in children. More studies in this age group would further help in delineating the safety profile of JAK inhibitors in the pediatric population.
Adverse effects
• Risk of urinary tract infection, nasopharyngitis, and upper respiratory tract infections • Varicella-zoster virus reactivation • Impaired response to vaccination • Thrombocytopenia, anemia • Diarrhea, fatigue, dizziness, and headache • Increased risk of malignancies. 
Monitoring guidelines
conclusion
In addition to the entities discussed, JAK inhibitors have also shown to be of value in chronic actinic dermatitis, erythema multiforme, cutaneous graft versus host disease, allergic contact dermatitis, melanoma, and cutaneous T-cell lymphoma. [60] [61] [62] [63] [64] [65] Based on the currently available data, tofacitinib has been found to be comparable with etanercept as a second-line agent for psoriasis. Further, owing to its oral route of administration and better economic profile over biologic drugs, tofacitinib again scores above them.
Moreover, when compared with other immunosuppressive drugs such as methotrexate, cyclosporine, azathioprine, and mycophenolate mofetil, JAK inhibitors have again elucidated superior results. Also, with topical preparations of JAK inhibitors being available, it could prove beneficial in those patients where systemic therapy with the drug is contraindicated or in milder disease phenotypes where topical therapy would suffice in bringing about disease remission, thereby representing a safer alternative for a number of chronic dermatologic diseases. However, more head-to-head comparative studies with respect to these drugs would further help in delineating things better. Overall, JAK inhibitors are a relatively safe group of drugs.
Today, JAK inhibitors are the subject of intensive research as they represent possible therapeutic targets in a number of cutaneous diseases.
Availability
• Tofacitinib is marketed as a 5 mg tablet under the brand name Xeljanz • Ruxolitinib is marketed as 5, 15, and 20 mg tablets under the brand name Jakavi • Baricitinib is marketed as 2 and 4 mg tablets under the brand name Olumiant • Tofacitinib is available as a 2% ointment • Ruxolitinib is available as a 0.6% ointment.
In India, currently, only the oral preparations of the above-mentioned JAK inhibitors are available.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
references
